

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**

26 February 2020

Change in Director's Interest

Zoono Group Limited (ASX:ZNO) attaches an Appendix 3Y, Change of Director's Interest Notice, for Managing Director, Mr. Paul Hyslop. Mr. Hyslop has divested 16.8M shares; reducing his shareholding from 51% to approximately 41%.

Mr. Hyslop founded the Zoono business 14 years ago. He funded the Company through a mixture of debt and (predominantly personal) equity until the Company listed on ASX following a \$10M public capital raise in May 2017. Other than a salary and a minor sell down on listing to cover tax incurred as a result of the transaction, Mr. Hyslop has not received any funds from the Company over that period. Proceeds from current sales will be used to retire some of the debt he has incurred in developing the Zoono business.

This week, during a trading window under the Company's Trading Policy and with the Board's blessing, Mr. Hyslop sold 1.5M shares on market at an average price of \$1.72/share. He also crossed 15.3M shares at \$1.35/share to Australian institutions. The major buyer was Regal Funds Management. Regal is one of Australia's leading investment managers and a very strong addition to the Company's share register.

Given the recent re-rating of the Company's share price following global interest in the Zoono technology, the Company has been approached by several fund managers seeking placements in the Company's securities. Zoono is well funded and does not require an injection of capital at this time, which would dilute current shareholders. The Managing Director's sale of a portion of his holding will contribute to liquidity in the Company's shares.

Mr. Hyslop has undertaken to enter a voluntary escrow agreement over his remaining holding for a period of 12 months. He remains the largest shareholder of Zoono with a dominant 41% interest going forward and committed to the continual development of the Company for the benefit of all shareholders.

This announcement has been authorised and approved for release by the Company Secretary of Zoono Group Limited.

For further information, please contact:

Elissa Hansen
Company Secretary
Zoono Group Limited
0411 764 556
elissa.hansen@zoono.com

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial

solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| |
|---|
| Name of entity Zoono Group Limited |
| ABN 73 006 645 754 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-------------|
| Name of Director | Paul Hyslop |
| Date of last notice | 5 May 2017 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| Direct or indirect interest | Indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Name of Holder Paul Russell Hyslop, Margaret Jane Morgan and NPT MEG Trustees Limited <MEG Trust> Nature of Interest The Director, together with his spouse and NPT MEG Trustees Limited, hold the shares as trustees for the MEG Trust. The Director is a beneficiary of the MEG Trust. |
| Date of change | 25 February 2020 |
| No. of securities held prior to change | 83,708,000 |
| Class | Fully paid ordinary shares |
| Number acquired | Nil |
| Number disposed | 16,800,000 |

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|---|
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | \$23,228,066.76 |
| No. of securities held after change | 66,558,000 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | 1,500,000 via on market trade 15,300,000 crossed on market |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

⁺ See chapter 19 for defined terms.

For personal use only